Social media

The next in our UK regulatory environment blog series is out now. In this instalment we discuss the opportunity for interactions with both the MHRA and the National Institute for Health and Care Excellence (NICE). These ...

When commercialising a multi-indication drug, a narrow first launch strategy targets high-value populations for premium pricing but may slow accumulation of real world evidence. Understand these trade-offs in our arti...

Medical writing teams play a central role in regulatory submissions, but success depends on more than writing skill alone. In this IBI article, our experts explore how planning, leadership and collaboration support hig...

Struggling to keep up with the explosion of life sciences research? Systematic literature reviews (SLRs) are your key to navigating the noise with clarity and rigor. Download our latest whitepaper to learn: - How to co...

From complexity to clarity. See how ICON’s blended delivery model provides flexible, scalable solutions to suit or partners’ evolving clinical needs. Explore real results in our blended solutions case studies: https://o...

Preparing clinical data for submission to both the FDA and PMDA can be demanding. But with shared expectations and overlapping standards, there is a clear opportunity to streamline the process. Our latest whitepaper offe...

Susie McEvoy's path at ICON illustrates what it means to grow with purpose. Since joining as an HR Project Analyst in 2013, Susie has pursued every opportunity - from pioneering new roles to seeking mentorship, ultimatel...

2025 survey insights reveal developers are divided on the best launch strategy for multi-indication therapies. Approximately 31% prefer launching in a broad population, while 27% favor starting with a narrower indication...

August is Psoriasis Awareness Month, honoring the 8+ million people in the U.S. living with this chronic condition. Behind every new treatment is a journey to understand what patients need, and what keeps them from stay...

For #NationalImmunisationAwarenessMonth our blog looks at the recent history and the future of vaccines. Vaccine developers have an active role to play in supporting individuals and physicians to make informed decisions ...

If you would like a convenient way to keep on top of the latest regulatory authority updates, sign up to our free newsletter. https://ow.ly/jY7C50WwH5E Compiled and collated by ICON’s Regulatory Intelligence Team and de...

Multi-indication development strategies help increase a drug candidate's overall value, but remain complex and increasingly expensive, requiring significant clinical, administrative and site monitoring costs. Learn how d...